Comparative efficacy of sacubitril valsartan and perindopril in post-AMI heart failure treatment after PCI
Objective To compare the effectiveness of sacubitril valsartan and perindopril in the treat-ment of heart failure in patients with acute myocardial infarction(AMI)following percutaneous coronary interven-tion(PCI).Methods A total of 112 AMI patients admitted to Cangnan County People's Hospital from January 2021 to June 2022 were selected,and were divided into the sacubitril valsartan group and the perindopril group based on their treatment outcomes.Both groups of patients received PCI and conventional drug treatment.The changes in cardiac function and incidence of adverse events before and after treatment were observed in both groups.Results Compared to the perindopril group,the N-terminal pro-B-type natriuretic peptide(NT-proBNP)levels was lower in sacubitril valsartan group.While there was no statistically significant difference in blood pres-sure control levels between the two groups.The heart rate improvement in the sacubitril valsartan group was better than that in the perindopril group(P＜0.05).Both groups were able to effectively improve the cardiac function,but the sacubitril valsartan group showed more significant improvement(P＜0.05).However,there was no statistically significant difference in the incidence of adverse events between two groups(P＞0.05).Conclusion Sacubitril val-sartan could be an effective medication choice in treating heart failure post-acute myocardial infarction and PCI.It seems to be superior to perindopril in improving cardiac function,reducing NT-proBNP levels,and stabiliz-ing heart rate.
万方数据
维普
